Amgen: Kidney Diseases trials

The registry lists 24 Kidney Diseases studies with Amgen as lead sponsor. 0 are open to participants now and 6 have results posted.

Phase 1 2Phase 2 1Phase 3 13Phase 4 8(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney DiseaseCompletedNCT01652872Phase 3Results posted
• Pediatric Chronic Kidney Disease Safety and EfficacyTerminatedNCT01277510Phase 3Results posted
• Treatment of Autonomous Hyperparathyroidism in Post Renal Transplant RecipientsCompletedNCT00975000Phase 3Results posted
• Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Patients With Chronic Kidney DiseaseTerminatedNCT00436748Phase 3Results posted
• ADVANCE: Study to Evaluate Cinacalcet Plus Low Dose Vitamin D on Vascular Calcification in Subjects With Chronic Kidney Disease Receiving HemodialysisCompletedNCT00379899Phase 4Results posted
• Trial to Reduce Cardiovascular Events With Aranesp® Therapy (TREAT)CompletedNCT00093015Phase 3Results posted
• A Study in Healthy Volunteers to Evaluate the Drug-Drug Interaction Potential of CCX168 With Concomitant MedicationsCompletedNCT06004947Phase 1
• A Pharmacokinetic Study of AMG 386 in Cancer Subjects With Normal and Impaired Renal FunctionCompletedNCT01331941Phase 1
• Study to Assess Fixed Dosing of AMG 223 in Subjects With Chronic Kidney Disease on Hemodialysis With HyperphosphatemiaCompletedNCT00530114Phase 2
• STAAR-1 Clinical StudyCompletedNCT00369772Phase 4
• STAAR-3 Clinical StudyCompletedNCT00369733Phase 4
• STAAR-2 Clinical StudyCompletedNCT00368901Phase 4
• START: Sensipar Treatment Algorithm to Reach K/DOQI Targets in Chronic Kidney Disease Subjects With Secondary HyperparathyroidismCompletedNCT00132431Phase 4
• An Evaluation of Aranesp® in Subjects With Anaemic Chronic Kidney Disease (CKD)CompletedNCT00124098Phase 3
• Efficacy Study: Darbepoetin Alfa for the Treatment of Anemia in Patients With Chronic Kidney DiseaseCompletedNCT00121602Phase 3
• Study to Evaluate Effectiveness of Aranesp®CompletedNCT00117130Phase 4
• Evaluating Aranesp® in Subjects With End Stage Renal Disease onChronic HemodialysisCompletedNCT00117104Phase 4
• Aranesp® Monthly Preference Study - 2CompletedNCT00117078Phase 4
• Treatment for Subjects With Chronic Kidney Disease Receiving HaemodialysisCompletedNCT00116701Phase 3
• Study for Subjects With Chronic Kidney Disease(CKD) Not Receiving DialysisCompletedNCT00112008Phase 3
• Treatment for Subjects With Chronic Kidney Disease (CKD) Not Receiving DialysisCompletedNCT00111098Phase 3
• Study Evaluating Darbepoetin Alfa in Subjects With Chronic Kidney Disease (CKD) Receiving DialysisCompletedNCT00096915Phase 3
• Cinacalcet HCl in Chronic Kidney Disease Subjects With Secondary Hyperparathyroidism Not Receiving DialysisCompletedNCT00094484Phase 3
• Study to Assess Darbepoetin Alfa in Subjects With Chronic Kidney DiseaseCompletedNCT00093977Phase 3